121 related articles for article (PubMed ID: 19048622)
1. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors.
Varna M; Lehmann-Che J; Turpin E; Marangoni E; El-Bouchtaoui M; Jeanne M; Grigoriu C; Ratajczak P; Leboeuf C; Plassa LF; Ferreira I; Poupon MF; Janin A; de Thé H; Bertheau P
Int J Cancer; 2009 Feb; 124(4):991-7. PubMed ID: 19048622
[TBL] [Abstract][Full Text] [Related]
2. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
3. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
4. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy.
Bertheau P; Plassa F; Espié M; Turpin E; de Roquancourt A; Marty M; Lerebours F; Beuzard Y; Janin A; de Thé H
Lancet; 2002 Sep; 360(9336):852-4. PubMed ID: 12243922
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.
Kandioler-Eckersberger D; Ludwig C; Rudas M; Kappel S; Janschek E; Wenzel C; Schlagbauer-Wadl H; Mittlböck M; Gnant M; Steger G; Jakesz R
Clin Cancer Res; 2000 Jan; 6(1):50-6. PubMed ID: 10656431
[TBL] [Abstract][Full Text] [Related]
6. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
7. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
[TBL] [Abstract][Full Text] [Related]
8. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
[TBL] [Abstract][Full Text] [Related]
9. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
11. Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.
Oshima K; Naoi Y; Kishi K; Nakamura Y; Iwamoto T; Shimazu K; Nakayama T; Kim SJ; Baba Y; Tamaki Y; Noguchi S
Cancer Lett; 2011 Aug; 307(2):149-57. PubMed ID: 21514041
[TBL] [Abstract][Full Text] [Related]
12. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
13. Changes in allelic imbalances in locally advanced breast cancers after chemotherapy.
Varna M; Soliman H; Feugeas JP; Turpin E; Chapelin D; Legrès L; Plassa LF; de Roquancourt A; Espié M; Misset JL; Janin A; de Thé H; Bertheau P
Br J Cancer; 2007 Oct; 97(8):1157-64. PubMed ID: 17876337
[TBL] [Abstract][Full Text] [Related]
14. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
15. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
Ooe A; Kato K; Noguchi S
Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
[TBL] [Abstract][Full Text] [Related]
16. Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis.
Loehberg CR; Thompson T; Kastan MB; Maclean KH; Edwards DG; Kittrell FS; Medina D; Conneely OM; O'Malley BW
Cancer Res; 2007 Dec; 67(24):12026-33. PubMed ID: 18089834
[TBL] [Abstract][Full Text] [Related]
17. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
[TBL] [Abstract][Full Text] [Related]
18. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
19. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
[TBL] [Abstract][Full Text] [Related]
20. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs.
Chang BD; Xuan Y; Broude EV; Zhu H; Schott B; Fang J; Roninson IB
Oncogene; 1999 Aug; 18(34):4808-18. PubMed ID: 10490814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]